Translucent brain with glowing neural signaling pathways — Zermatt Biotech scientific focus on neuroinflammatory disease
Science · Pipeline

Our Scientific
Focus

Tackling rare neuroinflammatory disease at the level of mechanism — built on AI-driven signaling pathway modeling.

Lead Program: AGS View Pipeline
Lead Program

Aicardi–Goutières Syndrome (AGS)

  • Neuroinflammatory rare disease

    Severe neurological symptoms emerging in infancy or early childhood.

  • Genetic dysregulation of innate immunity

    Loss-of-function mutations in nucleic-acid-handling enzymes trigger chronic type-I IFN signaling.

  • No disease-modifying therapies

    Current standard of care is supportive only.

Artistic visualization of neural signaling activity at the cellular level — AGS research focus
<1 in 100,000
Prevalence — among the rarest pediatric neuroinflammatory conditions
7+
Known causal genes — TREX1, RNASEH2A/B/C, SAMHD1, ADAR1, IFIH1
0
Approved disease-modifying therapies — a wide-open mechanism opportunity

Stats pending final scientific review. Contact our team for updated references.

Hypothesis

"Dysregulated innate immune signaling drives chronic neuroinflammation in AGS."

Our Strategy

A three-step mechanism-first approach — from upstream drivers to therapeutic candidates.

1

Identify

Identify upstream pathway drivers using mechanistic AI on patient multi-omics data.

2

Validate

Validate mechanistic targets in disease-relevant biology — patient-derived cells and models.

3

Develop

Develop therapeutic candidates against validated targets — small molecule, biologic, or modality-agnostic.

Beyond AGS

Our mechanistic platform is designed to generalize across innate-immunity-driven disease.

Other neuroinflammatory diseases

Shared interferon signaling pathways

Autoimmune disorders

Type-I IFN-driven pathology

Rare genetic conditions

Monogenic immune dysregulation

Program Pipeline

Current programs across discovery and preclinical stages.

Program Indication Discovery Preclinical IND-Enabling Phase 1
ZMT-001 Aicardi–Goutières Syndrome
ZMT-102 Neuroinflammation (TBD)
ZMT-205 Autoimmune (TBD)

Filled squares represent current progress within stage. Hover rows for context. Contact us for pipeline detail.